Aurobindo Pharma arm ties up with European firm for biosimilars

Aurobindo Pharma subsidiary CuraTeQ Biologics has entered into a marketing and distribution agreement with European healthcare and pharmaceuticals company STADA Arzneimittel AG for two biosimilars.

Under the agreement, STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories, including France and Germany. New brand names will be created and registered for each biosimilar, Aurobindo Pharma said in a filing.

The agreement is expected to expand CuraTeQ’s market reach, drive revenue growth, and leverage STADA’s established distribution network in EU markets, it said.